Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.

Summary

In a 72-week, multicenter, double-blind phase 3 trial (n=1613), once-daily oral orforglipron (6–36 mg) produced statistically superior bodyweight reduction versus placebo as an adjunct to lifestyle modification in adults with type 2 diabetes and overweight/obesity. Completion was high (89.5%), and adverse events were consistent with the GLP-1RA class profile.

Key Findings

• Adults with T2D and BMI ≥27 kg/m2 randomized to orforglipron (6, 12, or 36 mg) had statistically greater bodyweight reduction versus placebo at 72 weeks.
• High study completion (89.5%) across 136 sites in 10 countries supports feasibility and tolerability.
• Adverse events were consistent with GLP-1RA class effects, with no unexpected safety signals reported.

Clinical Implications

Orforglipron could expand incretin-based obesity management for type 2 diabetes to an oral option, potentially improving adherence and facilitating earlier combination strategies; safety monitoring should follow class-consistent GI AEs.

Limitations

• Industry-sponsored trial; detailed glycemic and cardiometabolic secondary outcomes not fully described in abstract
• Generalizability may vary across populations and comorbidities; long-term cardiovascular outcomes not reported

Future Directions

Head-to-head comparisons with injectable GLP-1RAs, durability beyond 72 weeks, cardiometabolic outcomes, and combination with SGLT2 inhibitors or tirzepatide-like agents.